Want to see GB:AREC full AI Analyst Report?
AREC Stock Chart & Stats
85.00 p
-0.75 p(-1.01%)
At close: 4:00 PM EST
85.00 p
-0.75 p(-1.01%)
Day’s Range― - ―
52-Week Range55.27 p - 95.00 p
Previous CloseN/A
Volume5.49K
Average Volume (3M)31.44K
Market Cap
£37.37M
Enterprise Value20.50M
Total Cash (Recent Filing)£3.15M
Total Debt (Recent Filing)£57.00K
Price to Earnings (P/E)165.0
Beta0.67
Next Earnings
Apr 27, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding45,300,716
10 Day Avg. Volume38,413
30 Day Avg. Volume31,437
Financial Highlights & Ratios
PEG Ratio-0.43
Price to Book (P/B)4.71
Price to Sales (P/S)17.73
P/FCF Ratio-12.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.12
Revenue Forecast (FY)£300.00K
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low leverage gives Arecor a stronger financial base than its operating results alone would suggest. Minimal debt reduces interest and refinancing pressure, preserves flexibility for development spending, and provides greater resilience while the company pursues partnerships and product opportunities.
Improving Cash BurnThe substantial reduction in annual free cash flow loss indicates progress in controlling cash consumption, even though the business remains cash-flow negative. If sustained, better cash discipline could extend funding runway and reduce the urgency of external financing.
Proprietary Formulation PlatformA proprietary formulation platform gives Arecor a focused technological basis for developing improved versions of established biologic medicines. Applications across insulin, diabetes care, and other therapeutic areas could support multiple partnering or licensing opportunities over time.
Bears Say
Sharp Revenue DeclineThe sharp 2025 revenue contraction demonstrates that commercial and partnership income remains volatile rather than steadily scaling. Such variability makes financial planning harder and suggests that future revenue may depend heavily on the timing of development, licensing, or milestone activity.
Persistent Operating LossesPersistently negative EBIT and EBITDA show that the core operating model has not yet reached profitability. Continued operating losses can consume equity and require ongoing funding, while also limiting the company’s ability to reinvest from internally generated earnings.
Ongoing Cash DependenceArecor is still not self-funding despite the improvement in 2025 cash burn. Continued negative operating and free cash flow creates reliance on financing, grants, or partnering proceeds, which may constrain strategic flexibility if external funding becomes less available.
Arecor Therapeutics PLC News
AREC FAQ
What was Arecor Therapeutics PLC’s price range in the past 12 months?
Arecor Therapeutics PLC lowest share price was 55.27 p and its highest was 95.00 p in the past 12 months.
What is Arecor Therapeutics PLC’s market cap?
Arecor Therapeutics PLC’s market cap is £37.37M.
When is Arecor Therapeutics PLC’s upcoming earnings report date?
Arecor Therapeutics PLC’s upcoming earnings report date is Apr 27, 2027 which is in 187 days.
How were Arecor Therapeutics PLC’s earnings last quarter?
Arecor Therapeutics PLC released its earnings results on Sep 30, 2026. The company reported -0.08 p earnings per share for the quarter.
Is Arecor Therapeutics PLC overvalued?
According to Wall Street analysts Arecor Therapeutics PLC’s price is currently Overvalued.
Does Arecor Therapeutics PLC pay dividends?
Arecor Therapeutics PLC does not currently pay dividends.
What is Arecor Therapeutics PLC’s EPS estimate?
Arecor Therapeutics PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Arecor Therapeutics PLC have?
Arecor Therapeutics PLC has 45,300,716 shares outstanding.
What happened to Arecor Therapeutics PLC’s price movement after its last earnings report?
Arecor Therapeutics PLC reported an EPS of -0.08 p in its last earnings report. Following the earnings report the stock price went down -18.079%.
Which hedge fund is a major shareholder of Arecor Therapeutics PLC?
Currently, no hedge funds are holding shares in GB:AREC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arecor Therapeutics PLC Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.32%
12-Months-Change
Fundamentals
Return on Equity
3.75%
Trailing 12-Months
Asset Growth
-11.43%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Arecor Therapeutics PLC
Arecor Therapeutics PLC is a biopharmaceutical enterprise dedicated to creating therapies for diabetes and various other medical conditions. The company utilizes its exclusive Arestat formulation technology platform to both cultivate its own range of specialized products (for diabetes and other ailments) and collaborate with pharmaceutical and biotechnology partners to refine and enhance existing therapeutic formulations. Its pipeline includes AT247, an exceptionally fast-acting insulin aimed at individuals with Type I and Type II diabetes, and AT278, a highly concentrated rapid-acting insulin formulation engineered to hasten insulin absorption following injection. Established in 2007, the company's main office is situated in Little Chesterford, United Kingdom.
Technical Analysis
Avacta Group plc
―
Bioventix
―
Oxford BioMedica
―
Fusion Antibodies Plc
―
Aptamer Group Plc
―